UroGen Pharma Ltd. (URGN) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$33.04

From 52W high−41.70%

Volume1.96M

Market cap$1.43B

P/E (TTM)—

P/S (TTM)7.6x

Div yield—

Key dataNov 4, 2026

Open

$33.04

From 52W high

−41.70%

Volume

1.96M

Market cap

$1.43B

ValuationView details →

P/E (Fwd)

13.7x

EV/EBITDA

−21.7x

P/E (TTM)

—

RSI (14)

26.3

MomentumView details →

1D Return

−14.76%

YTD Return

+29.31%

SummaryUpdated Jun 1, 2026

UroGen Pharma Ltd. (NASDAQ:URGN) is a biotechnology company founded in 2004 and based in Princeton, New Jersey, that specializes in developing and commercializing novel treatments for specialty cancers and urothelial diseases. The company went public in May 2017 and has established itself as a focused player in the urological oncology space, with its flagship product <b>JELMYTO</b> already commercialized and a promising pipeline of investigational therapies targeting various forms of bladder and upper tract cancers.

Ask drillr about UroGen Pharma Ltd. →

ValuationView details →

P/E (Fwd)

13.7x

P/E (TTM)

—

EV/EBITDA

−21.7x

EV/Sales

8.1x

P/S (TTM)

7.6x

P/B (TTM)

−10.8x

ProfitabilityView details →

Gross Margin

90.85%

Net Margin

−51.73%

EBITDA Margin

−37.16%

ROE (TTM)

73.75%

ROA (TTM)

−38.65%

Asset Turnover

0.75x

GrowthView details →

Revenue YoY

+100.27%

EPS YoY

+40.36%

FCF YoY

−28.83%

Revenue CAGR 3Y

+19.49%

EPS CAGR 3Y

−7.77%

EBITDA YoY

+45.59%

MomentumView details →

1D Return

−14.76%

YTD Return

+29.31%

1Y Return

+56.84%

RSI (14)

26.3

vs 50D SMA

−23.59%

vs 200D SMA

−3.90%

Capital & dividendView details →

Debt/Equity

−1.48x

Current Ratio

3.80x

Quick Ratio

3.41x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.03

EPS Surprise

−128.38%

Beats (12Q)

5/12

Next Q EPS Est

$0.44

Avg Surprise (4Q)

−28.45%

Rev Surprise

−1.02%

Financials snapshotView financials →

Revenue (TTM)

188.73M

Net Income (TTM)

−97.64M

Op. CF (TTM)

−158.92M

Next earningsNov 5, 2026 →

Latest newsMore news →

UroGen Pharma Ltd. reported a third-quarter loss of $0.03 per share, compared with a loss of $0.69 per share a year earlier.3h ago

UroGen Pharma reported that ZUSDURI generated $68.0 million in revenue in the third quarter of 2026, up 35% quarter over quarter.6h ago

Similar companies

KalVista Pharmaceuticals, Inc.KALV Structure Therapeutics Inc.GPCR Guangzhou Innogen Pharmaceutl Grp Co Ltd02591.HK AnaptysBio, Inc.ANAB Kardigan, Inc.KARD SinoMab BioScience Limited03681.HK Find similar companies →

Latest newsMore news →

UroGen Pharma Ltd. reported a third-quarter loss of $0.03 per share, compared with a loss of $0.69 per share a year earlier.3h ago UroGen Pharma reported that ZUSDURI generated $68.0 million in revenue in the third quarter of 2026, up 35% quarter over quarter.6h ago